As of January 8, 2016, Restorgenex Corporation was acquired by Diffusion Pharmaceuticals LLC, in a reverse merger transaction. RestorGenex Corporation operates as a specialty biopharmaceutical company that focuses on developing products for ophthalmology, oncology, and dermatology. Its lead product is a novel PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company’s pipeline also includes a “soft” anti-androgen compound for the treatment of acne vulgaris. The company was formerly known as Stratus Media Group, Inc. and changed its name ...
2150 East Lake Cook Road
Buffalo Grove, IL 60089
Restorgenex Corporation Announces Board Changes
Jan 8 16
In connection with the completion of the Merger and in accordance with the terms of the Merger Agreement, the Board of Directors of Restorgenex Corporation accepted the resignations from the Board of Directors and each of its committees of the following directors of the company, constituting all of the directors of the company prior to the Merger, with such resignations effective immediately prior to the effective time: Sol J. Barer, Ph.D., Isaac Blech, Rex Bright, Stephen M. Simes and Nelson K. Stacks. The Board of Directors also accepted the resignations of the following executive officers of the company, constituting all of the executive officers of the company prior to the Merger, with such resignations effective immediately prior to the Effective Time: Stephen M. Simes as Chief Executive Officer, Phillip B. Donenberg as Chief Financial Officer and Secretary, and Mark A. Weinberg, M.D. as Senior Vice President, Clinical Development. Also in connection with the completion of the Merger and in accordance with the terms of the Merger Agreement, the outgoing directors, prior to their resignation and in accordance with the company’s bylaws, fixed the number of directors at six, and appointed the following six individuals, constituting all of the directors of Diffusion prior to the Merger, to serve as directors of the Company, effective at the Effective Time and until the Company’s next annual meeting of stockholders, and until their respective successors are elected and qualified or until their earlier resignation or removal: David G. Kalergis, John L. Gainer, Thomas Byrne, Robert Adams, Mark T. Giles and Alan Levin. David G. Kalergis was appointed Chairman of the Board. Each of the new directors is entitled to participate in the company’s 2015 Equity Incentive Plan.
RestorGenex Corporation Announces Earnings Results for the Nine Months Ended September 30, 2015
Nov 12 15
RestorGenex Corporation announced earnings results for the nine months ended September 30, 2015. For the period, the company incurred a net loss of $20.7 million or $1.11 per share compared to net loss of $9.3 million or $0.76 per share for the same period last year. The primary reason for the increase in net loss was an $11.1 million non-cash impairment of goodwill during the period.
Restorgenex Corporation Presents at Dawson James Securities 2015 Growth Stock Conference, Oct-15-2015 11:15 AM
Sep 28 15
Restorgenex Corporation Presents at Dawson James Securities 2015 Growth Stock Conference, Oct-15-2015 11:15 AM. Venue: Wyndham Grand Hotel, Jupiter, Florida, United States.